The goals of this study were ( 1 ) to assure the dose of quinidine and timing relative to cilostazol used in this study were adequate to cause inhibition of CYP2D6 , ( 2 ) to evaluate carryover effects of quinidine administration , and ( 3 ) to evaluate the effect of CYP2D6 deficiency and administration of quinidine ( a CYP2D6 inhibitor ) on the pharmacokinetics of a single 100 mg oral dose of cilostazol .
